Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2001-09-07
2009-10-20
Ouspenski, Ilia (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S388100, C530S388220, C530S388750, C424S141100, C424S142100, C424S143100, C424S144100
Reexamination Certificate
active
07605238
ABSTRACT:
The present invention provides human sequence antibodies against human CTLA-4 and methods of treating human diseases, infections and other conditions using these antibodies.
REFERENCES:
patent: 4399216 (1983-08-01), Axel
patent: 4681581 (1987-07-01), Coates
patent: 4683195 (1987-07-01), Mullis
patent: 4683202 (1987-07-01), Mullis
patent: 4735210 (1988-04-01), Goldenberg
patent: 4740461 (1988-04-01), Kaufman
patent: 4816397 (1989-03-01), Boss
patent: 4921040 (1990-05-01), Ueruenduel et al.
patent: 4959455 (1990-09-01), Clark
patent: 5101827 (1992-04-01), Goldenberg
patent: 5151510 (1992-09-01), Stec
patent: 5194594 (1993-03-01), Khawli
patent: 5434131 (1995-07-01), Linsley
patent: 5530101 (1996-06-01), Queen
patent: 5545806 (1996-08-01), Lonberg et al.
patent: 5545807 (1996-08-01), Surani
patent: 5556763 (1996-09-01), Ochoa et al.
patent: 5569825 (1996-10-01), Lonberg et al.
patent: 5585089 (1996-12-01), Queen
patent: 5591669 (1997-01-01), Krimpenfort
patent: 5612205 (1997-03-01), Kay
patent: 5625126 (1997-04-01), Lonberg et al.
patent: RE35500 (1997-05-01), Rhodes
patent: 5633425 (1997-05-01), Lonberg et al.
patent: 5643763 (1997-07-01), Dunn
patent: 5648471 (1997-07-01), Buttram
patent: 5661016 (1997-08-01), Lonberg et al.
patent: 5693761 (1997-12-01), Queen
patent: 5693792 (1997-12-01), Torii
patent: 5697902 (1997-12-01), Goldenberg
patent: 5703057 (1997-12-01), Johnston
patent: 5714350 (1998-02-01), Co
patent: 5721367 (1998-02-01), Kay
patent: 5733743 (1998-03-01), Johnson
patent: 5741957 (1998-04-01), Deboer
patent: 5750172 (1998-05-01), Meade
patent: 5756687 (1998-05-01), Denman et al.
patent: 5770197 (1998-06-01), Lisley et al.
patent: 5770429 (1998-06-01), Lonberg et al.
patent: 5773253 (1998-06-01), Linsley et al.
patent: 5777085 (1998-07-01), Co et al.
patent: 5789215 (1998-08-01), Berns et al.
patent: 5789650 (1998-08-01), Lonberg et al.
patent: 5811097 (1998-09-01), Allison et al.
patent: 5814318 (1998-09-01), Lonberg et al.
patent: 5821332 (1998-10-01), Godfrey et al.
patent: 5827690 (1998-10-01), Meade et al.
patent: 5844095 (1998-12-01), Linsley et al.
patent: 5855887 (1999-01-01), Allison et al.
patent: 5874299 (1999-02-01), Lonberg et al.
patent: 5877397 (1999-03-01), Lonberg et al.
patent: 5885796 (1999-03-01), Linsley et al.
patent: 5916771 (1999-06-01), Hori et al.
patent: 5939598 (1999-08-01), Kucherlapati et al.
patent: 5968510 (1999-10-01), Linsley et al.
patent: 5977318 (1999-11-01), Linsley et al.
patent: 6051227 (2000-04-01), Allison et al.
patent: 6075181 (2000-06-01), Kucherlapati et al.
patent: 6114598 (2000-09-01), Kucherlapati et al.
patent: 6150584 (2000-11-01), Kucherlapati et al.
patent: 6162963 (2000-12-01), Kucherlapati et al.
patent: 6207156 (2001-03-01), Kuchroo et al.
patent: 6255458 (2001-07-01), Lonberg et al.
patent: 6632927 (2003-10-01), Adair et al.
patent: 6682736 (2004-01-01), Hanson et al.
patent: 6719972 (2004-04-01), Gribben et al.
patent: 6984720 (2006-01-01), Korman et al.
patent: 7034121 (2006-04-01), Carreno et al.
patent: 7229628 (2007-06-01), Allison et al.
patent: 7452535 (2008-11-01), Davis et al.
patent: 2002/0039581 (2002-04-01), Carreno et al.
patent: 2002/0086014 (2002-07-01), Korman et al.
patent: 2005/0201994 (2005-09-01), Halk et al.
patent: 2005/0249700 (2005-11-01), Allison et al.
patent: 2006/0034844 (2006-02-01), Allison et al.
patent: 2205680 (1998-11-01), None
patent: 0 256 055 (1991-08-01), None
patent: 0 323 997 (1993-04-01), None
patent: 0613944 (1994-09-01), None
patent: 0 338 841 (1995-03-01), None
patent: 0 216 846 (1995-04-01), None
patent: 0682039 (1995-11-01), None
patent: 0 463 151 (1996-06-01), None
patent: 0 546 073 (1997-09-01), None
patent: WO 90/04036 (1990-04-01), None
patent: WO91/10741 (1991-07-01), None
patent: WO92/03918 (1992-03-01), None
patent: WO92/22645 (1992-12-01), None
patent: WO 92/22647 (1992-12-01), None
patent: WO 92/22670 (1992-12-01), None
patent: WO 93/00431 (1993-01-01), None
patent: WO93/12227 (1993-06-01), None
patent: WO94/02602 (1994-02-01), None
patent: WO94/25585 (1994-11-01), None
patent: WO 94/29444 (1994-12-01), None
patent: WO 95/01994 (1995-01-01), None
patent: WO 95/03408 (1995-02-01), None
patent: WO 95/05464 (1995-02-01), None
patent: WO 95/23859 (1995-09-01), None
patent: WO 95/24217 (1995-09-01), None
patent: WO95/33770 (1995-12-01), None
patent: WO 95/34320 (1995-12-01), None
patent: WO 96/14436 (1996-05-01), None
patent: WO 96/14865 (1996-05-01), None
patent: WO 96/22380 (1996-07-01), None
patent: WO97/07671 (1997-03-01), None
patent: WO-97/13852 (1997-04-01), None
patent: WO 97/20574 (1997-06-01), None
patent: WO 97/38137 (1997-10-01), None
patent: WO98/24884 (1998-06-01), None
patent: WO98/24893 (1998-06-01), None
patent: WO98/24893 (1998-06-01), None
patent: WO98/37757 (1998-09-01), None
patent: WO96/33735 (1998-10-01), None
patent: WO96/34096 (1998-10-01), None
patent: WO98/42752 (1998-10-01), None
patent: WO 98/46996 (1998-10-01), None
patent: WO 98/50433 (1998-11-01), None
patent: WO 00/00569 (2000-01-01), None
patent: WO00/10383 (2000-03-01), None
patent: WO 00/32231 (2000-06-01), None
patent: WO 00/37504 (2000-06-01), None
patent: WO00/37504 (2000-06-01), None
patent: WO 01/14424 (2001-03-01), None
Rudikoff et al., 1982, Proc. Natl. Acad. Sci. USA, , 79: 1979-1983.
Panka et al., 1988, Proc. Natl. Acad. Sci. USA, 85: 3080-3084.
Blair at al. “Cutting edge: CTLA-4 ligation delivers a unique signal to resting human CD4 T cells that inhibits interleukin-2 secretion but allows Bcl-XLinduction,” The J. of Immunology 22:1767 (1998).
Bluestone (1997) J. Immunol. 158:1989-1993.
Brunet et al., Immunol. Rev. 103-21-36 (1988).
Brunet at al., Nature 328:267-270(1987).
Chambers (1997) Curr. Opin. Immunol. 9:396-404.
Chambers et al., Immunity. 7:885-895(1997).
Clark (1986) Human Immunol. 16:100-113.
Damle et al., Proc. Natl. Acad. Sci. 78:5096-6001 (1981).
Dariavach et al., Eur. J. Immunol. 18:1901-1905 (1988).
Elsas et al. “Combination immunotherapy of B16 melanoma using anti-cytoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation,” J. Exp. Med. 190:355-366 (1999).
Fishwild et al. “High-avidity human IgGk monoclonal antibodies from a novel strain of minilocus mice,” Nature Biotechnology 14:845-851 (1996).
Freedman (1987) J. Immunol. 138:3260-3267.
Freeman (1989) J. Immunol. 143:2714-2722.
Gribben et al. “CTLA4 mediates antigen-specific apoptosis of human T cells,” Proc. Natl. Acad. Sci. USA 92:811-815 (1995).
Hurwitz at al. “CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma,” Proc. Natl. Acad, Sci. USA 95:10067-10071 (1998).
Hurwitz at al. “Immunotherapy of primary prostrate cancer in a transgenic model using a combination of CTLA-4 blockade and tumor cell vacine,” Cancer Research 60:2444-2448 (2000).
Kearney (1995) J. Immunol. 155:1032-1036.
Kohno et al., Cell. Immunol. 131-1-10 (1990).
Krummel et al. “CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation,” (1995) J. Exp. Med. 182:459-465).
Krummel at al. “CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells,” J. Exp. Med 183:2533-2540 (1996).
Krummel et al. “Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo,” (1996) Int'l Immunol. 8:519-523.
Kwon et al. “Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostrate cancer,” proc. Natl. Acad, Sci. USA 94:8099-8103 (1997).
Lafage-Pochitaloff at al.., Immunogenetics 31:198-201 (1990).
Leach et al. “Enhancement of antitumor immunity by CTLA-4 blockade,” Science. 271:1734-1736 (1996).
Lesslauer et al., Eur. J. Immunol. 16:1289-1296 (1986).
Lindsten et al., Science 244:339
Deo Yashwant M.
Halk Edward L.
Keler Tibor P.
Korman Alan J.
Lonberg Nils
Baker & Botts LLP
Medarex Inc.
Ouspenski Ilia
LandOfFree
Human CTLA-4 antibodies and their uses does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human CTLA-4 antibodies and their uses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human CTLA-4 antibodies and their uses will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4114723